Clinical utility of ramucirumab in advanced gastric cancer

Matthew MK Chan,1,2 Katrin M Sjoquist,1,3 John R Zalcberg4 1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; 2Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia; 3Cancer Care Centre, St George Hospital, Sydney, NSW, Austr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chan MMK, Sjoquist KM, Zalcberg JR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/753dbcc498084cff88f458d9a9342066
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:753dbcc498084cff88f458d9a9342066
record_format	dspace
spelling	oai:doaj.org-article:753dbcc498084cff88f458d9a93420662021-12-02T08:24:50ZClinical utility of ramucirumab in advanced gastric cancer1177-5491https://doaj.org/article/753dbcc498084cff88f458d9a93420662015-09-01T00:00:00Zhttps://www.dovepress.com/clinical-utility-of-ramucirumab-in-advanced-gastric-cancer-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Matthew MK Chan,1,2 Katrin M Sjoquist,1,3 John R Zalcberg4 1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; 2Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia; 3Cancer Care Centre, St George Hospital, Sydney, NSW, Australia; 4School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia Abstract: Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit the vascular endothelial growth factor (VEGF) pathway including anti-VEGF antibody therapy (eg, bevacizumab), inhibitors of angiogenic receptor tyrosine kinases (eg, sunitinib, sorafenib, apatinib, regorafenib), and inhibitors of vascular endothelial growth factor receptors (VEGFRs) (eg, ramucirumab). Ramucirumab, a VEGFR-2 inhibitor, is the first anti-angiogenic agent approved by the US Food and Drug Administration for use in the treatment of advanced gastric cancers. This review will focus on the clinical utility and potential use of ramucirumab in advanced gastric cancer. Keywords: ramucirumab, IMC-1121B, gastric cancer, vascular endothelial growth factor receptor-2, angiogenesis, targeted therapyChan MMKSjoquist KMZalcberg JRDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2015, Iss default, Pp 93-105 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Chan MMK Sjoquist KM Zalcberg JR Clinical utility of ramucirumab in advanced gastric cancer
description	Matthew MK Chan,1,2 Katrin M Sjoquist,1,3 John R Zalcberg4 1NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; 2Department of Medical Oncology, Central Coast Cancer Centre, Gosford Hospital, Gosford, NSW, Australia; 3Cancer Care Centre, St George Hospital, Sydney, NSW, Australia; 4School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia Abstract: Gastric cancer is currently the third most common cause of cancer deaths worldwide. Prognosis remains poor with most patients presenting with advanced or metastatic disease. A better understanding of angiogenesis has led to the investigation of drugs that inhibit the vascular endothelial growth factor (VEGF) pathway including anti-VEGF antibody therapy (eg, bevacizumab), inhibitors of angiogenic receptor tyrosine kinases (eg, sunitinib, sorafenib, apatinib, regorafenib), and inhibitors of vascular endothelial growth factor receptors (VEGFRs) (eg, ramucirumab). Ramucirumab, a VEGFR-2 inhibitor, is the first anti-angiogenic agent approved by the US Food and Drug Administration for use in the treatment of advanced gastric cancers. This review will focus on the clinical utility and potential use of ramucirumab in advanced gastric cancer. Keywords: ramucirumab, IMC-1121B, gastric cancer, vascular endothelial growth factor receptor-2, angiogenesis, targeted therapy
format	article
author	Chan MMK Sjoquist KM Zalcberg JR
author_facet	Chan MMK Sjoquist KM Zalcberg JR
author_sort	Chan MMK
title	Clinical utility of ramucirumab in advanced gastric cancer
title_short	Clinical utility of ramucirumab in advanced gastric cancer
title_full	Clinical utility of ramucirumab in advanced gastric cancer
title_fullStr	Clinical utility of ramucirumab in advanced gastric cancer
title_full_unstemmed	Clinical utility of ramucirumab in advanced gastric cancer
title_sort	clinical utility of ramucirumab in advanced gastric cancer
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/753dbcc498084cff88f458d9a9342066
work_keys_str_mv	AT chanmmk clinicalutilityoframucirumabinadvancedgastriccancer AT sjoquistkm clinicalutilityoframucirumabinadvancedgastriccancer AT zalcbergjr clinicalutilityoframucirumabinadvancedgastriccancer
_version_	1718398550196355072

Clinical utility of ramucirumab in advanced gastric cancer

Ejemplares similares